Share Name Share Symbol Market Type Share ISIN Share Description
Inion Oy LSE:IIN London Ordinary Share FI0009012918 EUR0.03
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 0.36p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services - - - - 0.27

Inion Oy Share Discussion Threads

Showing 276 to 300 of 300 messages
Chat Pages: 12  11  10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
30/4/2009
17:01
irene, Agreed on all points.
mikey34
30/4/2009
12:56
This is a sorry state of affairs. Considering the value of the products they have created it seems outrageous that this can be allowed to go to the wall. I would have thought that Smith & Nephew or Glaxo could have picked this up. And what about 3i? Maybe the Finnish government could help. The world needs these sorts of innovative products. Maybe they will be saved at the last minute, but I doubt it.
irenekent
16/8/2008
22:37
Volumes have been low of late, so how has the threshold been crossed ?
mmamuk2
15/8/2008
08:14
Nice news this am...barclays now hold some 9.2M shares and looks like they have crossed the threshold and upped their stake to 12.15% by moving 5% to 10% threshold as per the rns this morning..don't think this has been spotted yet. Dyor etc:-))
pre
11/8/2008
07:28
EGM on wednesday ...be interesting to see what developments are announced by the company...
pre
11/8/2008
07:22
Out-licensing agreement (Inion Oy) RNS Number : 0340B Inion Oy 11 August 2008 Inion Oy ("Inion or the "Company") Inion licenses bioactive bone regrowth technology to US company Curative Biosciences Inc. Tampere, Finland and Guildford, UK. 11 August 2008, Inion (LSE: IIN.L), today announces the signature of an out-licensing agreement with US company, Curative Biosciences Inc. (Waltham, MA), covering certain of its novel bioactive technologies for the promotion of bone regrowth and repair when treating patients undergoing orthopaedic surgical procedures. Under the terms of the licensing agreement, Curative Bioscience Inc. will pay to Inion a small upfront fee, development and sales milestones of up to US$2,025,000 and royalties on revenues generated from any products developed using the technology. The licensed technology is based on the use of N,N-dimethylacetamide (DMA) and its pharmaceutically acceptable salts and prodrugs, either alone or incorporated in resorbable polymer structures (such as plates, membranes and screws) for implantation in patients. Patent applications covering this technology in the UK and internationally have been filed and are pending. Chris Lee, Inion's CEO, said: "DMA was discovered to have bioactive properties in promoting bone repair and regrowth through research work undertaken at our Cambridge facility prior to its closing last year. Inion, however, is no longer pursuing early stage development work in this area as it focuses on the commercialisation of its existing product portfolio for spinal surgery and orthopaedic trauma. By out-licensing non-core intellectual property and technologies, such as DMA, we seek to realise the value resulting from our research through companies more focused in these areas." -ends- For further information, please contact: Inion Oy Tel: +44 (0)1483 685390 Chris Lee, Chief Executive Officer Julien Cotta, Chief Financial Officer Citigate Dewe Rogerson Tel: +44 (0)207 638 9571 Mark Swallow / David Dible About Inion (www.inion.com) Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative and unique biodegradable and bioactive surgical implants in selected high value orthopaedic market segments. Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion Optima* family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate patient rehabilitation. Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004 (ticker: IIN). The Company has offices in the UK and USA, and its head office, R&D and production facilities are in Tampere, Finland. This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement. This information is provided by RNS The company news service from the London Stock Exchange END
pre
11/8/2008
07:13
nice...rns out this am re:out-licensing agreement....looks like this is yet to be spotted today....
pre
07/8/2008
07:15
EGM next week....more positive news on the way? All indicators blue this am....well undervalued imo....
pre
06/8/2008
07:59
PRE, Agreed.The mkt has battered co's with small mkt caps and profits not in the bag now.But this co has excellent prospects long term for the patient investor IMO.
mikey34
06/8/2008
07:11
patience will be rewarded...looks like someone is in the know as you say irenekent...bodes well considering this is well undervalued imo, dyor etc:-)
pre
05/8/2008
16:12
Is there a new boss here?
sheilae
05/8/2008
15:44
Big jump today - as usual someone knows something in advance of an announcement I would bet and all before the new boss is installed.
irenekent
15/7/2008
20:52
The market is looking for real money, not hopes! This is the trouble with biotechnology type stocks, don't get me wrong, I appreciate many are doing a lot of good R & D, but that does not bring the money in. I'm a big RENE fan, when talking about their research, but I am VERY VERY cautious about investing in them. To be honest I can't see how today's news can impact on the share price at the companies current Market Cap. The total market potential is just so small and you have still got to compete with the current suppliers.
hyper al
15/7/2008
20:44
pre, I agree.... the wider mkt is the problem today. ,
mikey34
15/7/2008
07:20
This looks well undervalued here imo....excellent pre-close trading statement following now by a cracking rns re:regulatory approval...
pre
15/7/2008
07:09
Wonder how much this is worth to IIN....this will open up other markets imo, with the US already opening up imo:-)) Found it! It estimates that the US market for these procedures is worth approximately 318 million euro and 32 million euro, respectively.
pre
15/7/2008
07:06
Cracking RNS....regulatory approval obtained:-))))))) Regulatory Approval (Inion Oy) RNS Number : 0510Z Inion Oy 15 July 2008 Inion Oy ("Inion or the "Company") Inion receives 510(k) marketing clearance to sell its biodegradable graft containment systems in the USA for spinal fusion procedures Tampere, Finland and Guildford, UK. 15 July 2008, Inion (LSE: IIN.L), the company focused on the development and commercialisation of novel biodegradable medical implants, today announces it has received 510(k) marketing clearance from the US Food and Drug Administration (FDA) for its biodegradable graft containment systems for spinal fusion procedures. The US marketing clearance has been received for the Inion S-1* Anterior Cervical Fusion System, the Inion S-1* double-level plate and the Inion S-2* Anterior Thoraco-Lumbar Fusion System. These systems consist of biodegradable plates and screws, which are designed for bone graft containment in spinal fusion procedures. Such procedures are carried out as a treatment for a range of spinal conditions including ruptures and displacement of inter-vertebral discs. Inion's S-1* and Inion S-2* graft containment systems include implants intended for use along the entire length of the spine in conjunction with traditional rigid fixation. These new graft containment systems also incorporate a radiographic marker to the edges of the plates and to the tips of screws. These markers enable surgeons to view the position of the implants in post-operative x-ray without interfering with their assessment of the site of surgery and its healing progress. More than 183,000 cervical plating procedures (Ref. 1) and more than 10,000 anterior thoraco-lumbar plating procedures (Ref. 2) were performed in 2006 in the USA. The US market for these procedures was worth approximately EUR318 million and EUR32 million, respectively. The number of spinal plating procedures has since grown at an annual rate of approximately 30%. Inion's biodegradable implants offer significant clinical benefits over traditional metal materials, primarily in that they slowly and completely degrade over time into carbon dioxide and water, which are absorbed into the body. The Inion S-1* and Inion S-2* graft containment systems received CE Mark marketing clearance in Europe in August 2007 and September 2007, respectively. Chris Lee, Inion's CEO, said: "The US marketing clearance for our biodegradable spine products is great news. We are already seeing increased uptake of this important product line in Europe where awareness and acceptance of the clinical benefits of biodegradable medical implants is rapidly growing among surgeons, who are adopting this technology into their practice. Our aim now is to push these new biodegradable products aggressively into the US spine market where we believe it will make an attractive alternative to traditional metal plates and a strong driver of value for the Company." References 1. Spinemarket, Inc: US spinal implant market: Cervical plate analysis. 2007 2. Spinemarket, Inc: US spinal implant market: Anterior lumbar plating analysis. 2007 -ends- For further information, please contact: Inion Oy Tel: +44 (0)1483 685390 Chris Lee, Chief Executive Officer Julien Cotta, Chief Financial Officer Citigate Dewe Rogerson Tel: +44 (0)207 638 9571 Mark Swallow / David Dible About Inion (www.inion.com) Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative and unique biodegradable and bioactive surgical implants in selected high value orthopaedic market segments. Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion Optima* family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate patient rehabilitation. Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004 (ticker: IIN). The Company has offices in the UK and USA, and its head office, R&D and production facilities are in Tampere, Finland. This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement. This information is provided by RNS The company news service from the London Stock Exchange END REAZGGMNGDLGRZZ
pre
14/7/2008
19:39
Interesting extract from todays rns....not long to go before the results in August...this little tiddler looks to have been overlooked by the market in recent weeks but no doubt management appear very confident with the business as it currently stands: '....Ian Paling said: "Inion has undergone many important changes over the past two years and I believe is in an excellent position to capitalise on the innovative technology and products it has developed. I am looking forward to working with the Company's Board and management team and believe that my experiences in growing Corin and other companies will allow me to make a very positive contribution to the future growth of this business." Chris Lee, Inion CEO, said: "We strongly believe that Inion has turned an important corner following a period of significant change that saw the Company completely refocus and restructure itself in order to better leverage its unique biomaterial technologies to realise its long-term value potential. Goran played a significant role in this process as well as bringing important discipline to the management of the organisation and, on behalf of the management team and Board, I would like to thank him and wish him every success in the future with his other business interests.
pre
07/7/2008
19:09
mikey34...couldn't agree more....looks like its heading back up from here..reckon the pre close trading statement was positive imo and took the market by surprise....i'm expecing this to move back up from here over the coming days and weeks....
pre
07/7/2008
13:36
pre, I am at a loss(literally) to explain why this has fallen so far.
mikey34
07/7/2008
07:34
mm's on the offer...tick up coming?
pre
07/7/2008
07:13
Let's see what today brings....a bullish trading update from IIN...we should see this advance further from here imo...
pre
04/7/2008
08:32
imo, this fall looks well overdone over the past few weeks....today IIN have announced a bulllish update and are showing increasing strength in overseas market which bodes well:-)
pre
04/7/2008
07:24
Pre-close Trading Update (Inion Oy) RNS Number : 3088Y Inion Oy 04 July 2008 Inion Oy ("Inion or the "Company") Pre-close Trading Update Tampere, Finland and Guildford, UK. 4 July 2008, Inion (LSE: IIN.L), the company focused on the development and commercialisation of novel biodegradable medical implants, today provides an update on 2008 trading, ahead of its half-yearly results announcement expected in August 2008. Based on the unaudited figures for the six months to 30 June 2008, the Directors anticipate that revenues for the period will be approximately EUR2.6 million, up 12% on the corresponding period in 2007. Invoiced sales of EUR1.8 million for the second quarter were 115% higher than in the first quarter of 2008, and 34% higher than in the corresponding period in 2007. These positive trends lead us to believe that Inion is on track to meet current market expectations of circa EUR7.0 million in sales for the full year 2008. Significantly, within these growth figures there is evidence to suggest Inion is starting to gain traction in the important US market. Chris Lee, Inion's CEO, said: "We continue to make good progress with executing our commercial strategy and are pleased to see sales growing strongly across our focused market segments. This uplift in sales is as a result of our commercial teams in these areas becoming more effective and an increasing awareness and acceptance among surgeons of the clinical benefits our biodegradable products can bring." -ends- For further information, please contact: Inion Oy Tel: +44 (0)1483 685390 Chris Lee, Chief Executive Officer Julien Cotta, Chief Financial Officer Citigate Dewe Rogerson Tel: +44 (0)207 638 9571 Mark Swallow / David Dible About Inion (www.inion.com) Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative and unique biodegradable and bioactive surgical implants in selected high value orthopaedic market segments. Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion Optima* family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate patient rehabilitation. Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004 (ticker: IIN). The Company has offices in the UK and USA, and its head office, R&D and production facilities are in Tampere, Finland. This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement. This information is provided by RNS The company news service from the London Stock Exchange END TSTFKNKDOBKDQOK
pre
04/7/2008
07:22
Nice positive pre-close trading update....fall was overdone here by the looks of things..
pre
Chat Pages: 12  11  10  9  8  7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20161204 08:17:48